Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

Labcorp posts strong Q3 growth, raises 2026 guidance, and accelerates specialty testing expansion.

What the company is saying

Labcorp emphasizes robust financial performance for Q3 2026, highlighting a 6.9% revenue increase to $3.81 billion and a 14.5% rise in adjusted EPS to $4.78. The company frames its narrative around continued margin expansion, innovation in specialty testing, and strategic M&A, with CEO Adam Schechter attributing results to organic growth and operating efficiencies. Labcorp raises its full-year 2026 guidance, projecting enterprise revenue growth of 5.9% to 6.7% and adjusted EPS of $18.30 to $18.70. The announcement details four M&A transactions—one closed (MLM Medical Labs) and three pending regulatory approval—each expected to be accretive to adjusted EPS in year one and to return cost of capital by year three. The company also spotlights FDA approval for its PGDx elio tissue complete CDx test and the launch of new specialty diagnostics, reinforcing its leadership in advanced testing. The tone is confident, with a focus on execution and capital discipline, supported by quantified results and explicit guidance updates.

What the data suggests

The disclosed numbers show clear operational and financial momentum. Q3 2026 revenue rose to $3.81 billion from $3.56 billion, with diluted EPS up 3.3% to $3.22 and adjusted EPS up 14.5% to $4.78. Diagnostics Laboratories revenue grew 6.5% to $2,948.9 million, with a 16.7% adjusted operating margin, while Biopharma Laboratory Services revenue climbed 8.5% to $866.7 million and margin improved to 18.3%. Operating cash flow reached $563.8 million, capital expenditures were $151.6 million, and free cash flow was $412.2 million. For the nine months ended September 30, 2026, revenue totaled $11,078.7 million and adjusted EPS was $14.02. The company invested $255.5 million in acquisitions and paid $58.2 million in dividends, ending the quarter with $261.8 million in cash and $5.85 billion in debt. Backlog stands at $8.92 billion, with a book-to-bill of 1.10. Updated 2026 guidance calls for enterprise revenue of $14,779–$14,887 million and adjusted EPS of $18.30–$18.70. Management attributes margin gains to organic growth and operating efficiencies. The evidence supports the company’s claims of growth and improved profitability, with forward-looking statements about M&A accretion and cost of capital return remaining projections.

Analysis

The announcement is highly factual and supported by detailed, realised financial and operational data. Revenue, EPS (both GAAP and adjusted), segment margins, cash flow, and free cash flow are all disclosed for the current and prior periods, demonstrating measurable improvement. Forward-looking statements (such as raised guidance and M&A accretion expectations) are clearly separated from realised results and are not exaggerated relative to the evidence. The only forward-looking claims relate to updated guidance and M&A accretion, but these are proportionate and grounded in the company's recent performance and closed transactions. There is no evidence of narrative inflation or overstatement; the tone is positive but justified by the underlying numbers. Capital outlays are matched by immediate or near-term earnings and cash flow, with no indication of long-dated, uncertain returns.

Risk flags

• ●Execution risk exists around the three pending acquisitions, which are subject to regulatory approvals and customary closing conditions. If approvals are delayed or terms change, expected accretion and strategic benefits could be deferred or reduced.
• ●The company’s total debt of $5.85 billion remains significant relative to its cash balance of $261.8 million, increasing sensitivity to interest rates and refinancing conditions, especially if cash flow growth slows.
• ●M&A integration risk is present, as Labcorp must successfully combine newly acquired businesses across the United States, Germany, and South Africa to realize projected synergies and cost of capital returns within three years.
• ●Guidance upgrades are predicated on continued organic growth and operating efficiencies; any deterioration in market demand, reimbursement rates, or cost pressures could challenge margin expansion and EPS targets.
• ●The company’s capital allocation strategy includes substantial ongoing investments ($255.5 million in acquisitions this quarter), which could pressure free cash flow if acquisition returns are slower than projected or if operational disruptions occur.

Bottom line

Labcorp’s Q3 2026 results demonstrate strong revenue and earnings growth, with both GAAP and adjusted metrics improving year-over-year. The company’s raised 2026 guidance and detailed segment performance provide credible evidence of operational momentum. Strategic M&A is a central theme, with one acquisition closed and three more pending, all expected to be accretive within a year and to return cost of capital by year three, though these outcomes depend on timely regulatory approvals and successful integration. Specialty testing expansion, FDA approvals, and new product launches reinforce Labcorp’s competitive positioning. The company’s high debt load and ongoing acquisition activity introduce financial and execution risks, but robust cash flow and a $1.4 billion share repurchase authorization provide some flexibility. Investors should focus on the pace of regulatory clearances for pending deals, realized synergies from acquisitions, and the company’s ability to sustain margin gains. The most important takeaway is that Labcorp is delivering on its growth narrative with tangible results, but continued execution on M&A and cost discipline will be critical to meeting elevated guidance.

Announcement summary

(NYSE:LH) Labcorp Holdings Inc. reported third quarter 2026 revenue of $3.81 billion, an increase from $3.56 billion in the third quarter of 2025, representing 6.9% growth. Diluted EPS for the quarter was $3.22 compared to $3.12 in the prior year period, up 3.3%. Adjusted EPS rose to $4.78 from $4.18, a 14.5% increase. The company raised its full-year 2026 enterprise revenue growth guidance to a range of 5.9% to 6.7%, up 50 basis points at the midpoint, and increased its adjusted EPS guidance to a range of $18.30 to $18.70, up $0.18 at the midpoint. Labcorp advanced its M&A strategy by announcing or closing four transactions, each expected to be accretive to adjusted EPS in year one and to return cost of capital by year three. The company received FDA approval for the PGDx elio® tissue complete CDx as a companion diagnostic for advanced melanoma. Labcorp launched new specialty tests for advanced melanoma, Alzheimer's disease, and hepatitis D, and expanded its OnDemand test menu to over 140 panels and tests. The company acquired MLM Medical Labs, with operations in the United States, Germany, and South Africa, and announced agreements to acquire select assets of BioReference Health, Myriad Genetics' Prenatal Health testing business, and Millennium Health. Labcorp invested $255.5 million in acquisitions and paid $58.2 million in dividends during the quarter. As of quarter end, cash and cash equivalents were $261.8 million and total debt was $5.85 billion. The company announced a quarterly cash dividend of $0.72 per share, payable December 11, 2026, to shareholders of record as of November 24, 2026. Labcorp has $1.4 billion remaining under its board-authorized share repurchase program. Diagnostics Laboratories segment revenue was $2,948.9 million, up 6.5%, with adjusted operating income of $491.6 million and a margin of 16.7%. Biopharma Laboratory Services segment revenue was $866.7 million, up 8.5%, with adjusted operating income of $159.0 million and a margin of 18.3%. Operating cash flow for the quarter was $563.8 million, capital expenditures were $151.6 million, and free cash flow was $412.2 million. For the nine months ended September 30, 2026, total revenue was $11,078.7 million, up from $10,435.9 million in 2025. Adjusted EPS for the nine months was $14.02, up from $12.37. As of September 30, 2026, trailing twelve months net orders were $3.59 billion, book to bill was 1.10, and backlog was $8.92 billion. The company forecasts next twelve months backlog conversion of $2.82 billion. Updated 2026 guidance includes enterprise revenue of $14,779 million to $14,887 million, Diagnostics Laboratories revenue of $11,475 million to $11,551 million, Biopharma Laboratory Services revenue of $3,328 million to $3,358 million, adjusted EPS of $18.30 to $18.70, and free cash flow of $1,240 million to $1,360 million.

Disagree with this article?